Phaseline

Targets › TAG72

TAG72: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Nov 2028.

Open in Phaseline: the race on TAG72, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
City of Hope Medical CenterTAG72-CAR T cells
Chimeric antigen receptor T-cell therapy targeting TAG72
TAG72Phase 1Platinum-Resistant Ovarian CarcinomaNov 2028

Conditions

Platinum-Resistant Ovarian Carcinoma (1)

Modalities

mixed (1)

Companies

City of Hope Medical Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.